This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
Currently there are no upcoming events.
Hosted by the Cancer Research Institute this intimate, invitation-only event for media and health care investment analysts will explore what’s next in the IO field.
Drs. Jill O'Donnell-Tormey and Vanessa M. Lucey are participating in panel discussions at Cancer Progress.
Laura Peace, Consultant, Head of Clinical Alliances, Clinical Accelerator, participates in a panel discussion, 10:30 a.m.-11:15 a.m.
Update on a CRI-funded pancreatic cancer trial led by Robert H. Vonderheide, M.D., D.Phil, on March 31 at 2:27 p.m.
CEO Jill O’Donnell-Tormey, Ph.D., participates in the Women in Science panel on March 3, 2019 at 2:30 p.m.
CRI scientists present at the Annual Meeting of the American Society of Clinical Oncologists. CRI provides a daily recap of new work coming out of the conference.
CRI-funded and -affiliated scientists and clinicians showcased at the American Association of Cancer Research Annual Meeting on April 14-18, 2018, in Chicago.
On April 12, our chief medical officer, Aiman Shalabi, is a featured expert on the panel, “Immuno-Oncology: Challenges & Opportunities”.
Dr. Jill O’Donnell-Tormey, CEO and director of scientific affairs, participates in the 'Weaponizing Your Own Body' panel on Tuesday, March 20, 2018 at 7:45 am.
Dr. Vanessa Lucey, associate director, CRI Venture Fund & Clinical Accelerator, speaks during the "Back to Basics" session on January 23, 2018 at 2:00 p.m.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
We spoke with Susanne Baumeister, M.D., about the current treatment landscape in childhood cancer, including immunotherapy and clinical trial options.
Dr. Michel Sadelain discusses what’s next in CAR T cell therapy, including the remarkable benefits and the challenges ahead for this incredibly promising immunotherapy approach.